Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

The trade for Hemarina is to have a pharma background ... is no old or new model, but there is old school thinking and open school thinking. We are clearly conscious of this within Sanofi and ...

French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...

On October 21, 2024, the 2024 business EPS guidance was upgraded to growth of at least a low single-digit percentage at CER supported by the ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Sanofi is now in “exclusive negotiations ... With the French government saying that it has received assurances from New York City-based CD&R that it will keep Opella’s manufacturing facilities ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Sanofi has returned with 300 million euros ($326 million) to set up a more permanent radioligand project. The new entity, which will operate under the Orano Med brand, will be focused on ...

A month after making a foray into the bustling radioligand field, Sanofi is further allying itself with Orano Med, paying ...

Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business.

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...